Iain Baird

Iain Baird is the principal of Development Solutions, a pharmaceutical consultancy firm focused on helping companies in Biological Pharmaceutical Development establish their Chemistry Manufacturing and Controls (CMC) capability.

Mr. Baird has supported over 50 companies in CMC development the last 11 years as well as working with the founders/CEOs of 6 companies starting companies developing new biological pharmaceutical products and CDMO’s providing services to the sector, including OSO BioPharmaceuticals Manufacturing, CANbridge Life Sciences, Gallus Biopharmaceuticals, Brammer Bio, Mikart Inc. and Vibalogics US Inc.

Prior to that Mr. Baird worked for 20 years, in the pharmaceutical and chemical industries. He started work for ICI which later became AstraZeneca. An engineer by discipline he initially designed and project managed the building of pharmaceutical facilities before moving into operational management running multiple production facilities in the United Kingdom. Since 2002 he has worked in the USA and was part of the leadership team that established the Avecia Oligonucleotides business as a CMO, taking a small team of researchers and growing it into an FDA approved manufacturing site with 150 employees. In 2006 Mr. Baird was one of the principles that established Avecia Vaccines in which he led the CMC groups in the development of vaccines against anthrax and plague.